

# Construction of Eukaryotic Expression Vectors Encoding CFP-10 and ESAT-6 Genes and Their Potential in Lymphocyte Proliferation

Azam Torabi<sup>1</sup>, Mojtaba Tahmoorespour<sup>1</sup>, Fatemeh Vahedi\*<sup>2</sup>,  
Nader Mosavari<sup>3</sup>, Mohammadreza Nassiri<sup>1</sup>

## Abstract

**Background:** *Mycobacterium (M.) bovis* is the agent of bovine tuberculosis (TB) in a range of animal species, including humans. Recent advances in immunology and the molecular biology of *Mycobacterium* have allowed identification of a large number of antigens with the potential for the development of a new TB vaccine. The ESAT-6 and CFP-10 proteins of *M. bovis* are important structural and functional proteins known to be important immunogens.

**Methods:** In the current study, the DNAs encoding these genes were utilized in the construction of pcDNA 3.1+/ESAT-6 and pcDNA3.1+/CFP-10 plasmids. After intramuscular injection of BALB/c mice with these plasmids, ESAT-6 and CFP-10 mRNA expression was assessed by RT-PCR. Mice were inoculated and boosted with the plasmids to evaluate their effects on lymphocyte proliferation.

**Results:** Our results indicate the plasmids are expressed at the RNA level and can induce lymphocyte proliferation.

**Conclusion:** Further study is needed to characterize the effect of these antigens on the immune system and determine whether they are effective vaccine candidates against *M. bovis*.

**Keywords:** BALB/c mice, CFP-10, DNA vaccine, ESAT-6, *Mycobacterium bovis*, PPD, Proliferation assay,

## Introduction

*Mycobacterium (M.) bovis* is a slow-growing, aerobic bacterium and the causative agent of tuberculosis (TB) in many domesticated and wild animals, in particular *Bovidae*, *Cervidae*, and occasionally carnivores and humans (1-3). More than 10% of human TB is caused by *M. bovis*. Bovine TB is a zoonotic disease that is seriously detrimental to the dairy industry (4). If a country's animals are infected with bovine TB, humans will always be threatened by it. If action is not taken to eliminate *M. bovis*, the control of human TB will be unsuccessful (5). The disease can occur sporadically and is difficult to eradicate. The introduction of milk pasteurization

in developed countries has dramatically reduced the transmission of TB from cattle to humans (6) but the causative agent of bovine TB, *M. bovis*, remains responsible for 5-10% of human TB cases (7). Artificial immunization and natural infections are difficult to differentiate in cattle and other animals, because after vaccination with Bacillus Calmette-Guérin (BCG), the results of allergic detection tests are always positive. Skin tests and slaughter policies have significantly reduced the incidence of bovine TB; however, trials have shown that the attenuated BCG vaccine does not provide consistent protection against TB (8, 9). Several major antigens such as

1: Department of Animal Science, Faculty of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran

2: Razi Vaccine and Serum Research Institute, Mashhad, Iran

3: Department of PPD and Tuberculin production, Razi Vaccine and Serum Research Institute, Karaj, Iran

\*Corresponding author: Fatemeh Vahedi; Tel: +98 511-8431780; Fax: +98 511-8420430;

E-mail: f.vahedi@rvsri.ac.ir, vahedif@yahoo.com

Received: Jul 12, 2013; Accepted: Aug 10, 2013

hsp60, Ag85, ESAT-6, and others have shown promise as new vaccine candidates (10, 11). Using these antigens, a number of diagnostic systems and vaccines have been developed (12).

The 10-kDa culture filtrate protein (CFP-10) and 6-kDa early-secreted target antigen (ESAT-6) are two low molecular weight secretory proteins encoded by the Rv3874 and Rv3875 genes, respectively. Both genes are located in the region of difference-1 (RD1) region of the *Mycobacterium (M.) tuberculosis* (MTB) genome, but absent in all *M. bovis* BCG vaccine strains. These proteins form a 1:1 heterodimeric complex, known as the CE protein (13). The ESAT-6/CFP-10 complex's secretion from and attachment to infected host cells demonstrates its contribution to the pathogenicity of *M. tuberculosis* (14).

The presence of antibodies against ESAT-6 and CFP-10 in patients with TB was confirmed, and it was demonstrated that significant antibody responses are not restricted to active TB disease but can also reflect latent infections (17).

Analysis of the MTB immunoproteome using high-throughput detection of antibodies in human serum against the entire MTB proteome revealed that CFP-10 is significantly associated with active TB (18).

ESAT-6 has recently been demonstrated to induce protective immunity when administered as a subunit or DNA vaccine (19).

Roles for these molecules in future TB vaccines have previously been suggested and these antigens have shown promise when delivered as DNA vaccines (20-23). The purpose of the present work

was to construct recombinant plasmids encoding the ESAT-6 and CFP-10 antigens as DNA vaccines, characterize their expression in BALB/c mice, and inoculate and boost mice to evaluate the plasmids' effects on lymphocyte proliferation.

## Materials and Methods

### *Bacterial Strains, Plasmid and mice*

Purified DNA of *M. bovis* (strain NA5) and bovine PPD (PPD-B) prepared from *M. bovis* were obtained from the PPD Tuberculin Department, Razi Vaccine and Serum Research Institute, Karaj, Iran (RVSRI).

*Escherichia (E) coli* strain Top 10 (Stratagene, USA) was used for cloning. The bacteria were grown in or on Luria-Bertani medium (LB) broth or agar supplemented, when required, with 50 µg/ml of ampicillin.

The eukaryotic expression vector pcDNA3.1(+) (Novagen, USA) was used for plasmid construction. All chemicals were purchased from Merck & Company, Inc. (Germany). Female BALB/c mice, 6-8 weeks of age, were provided by the animal house of RVSRI.

### *PCR amplification and cloning of ESAT-6 and CFP-10*

ESAT-6 and CFP-10 genes were amplified by PCR from the purified *M. bovis* strain NA5 DNA by the specific primers designed using Gene Runner and BioEdit software and data in Genbank, NCBI. The restriction sites were designed into the primers. The primers are shown in Table 1.

**Table 1.** Primers used in this study. Enzyme restriction sites are underlined.

Gene	Sequence	Restriction site
ESAT-6	Forward AGCA/AGCTTATTATGGGAACAGAGCAGCAGTGGAA	<i>Hind III</i>
	Reverse TATGCGAACATCCCAGTGACTGAGAGCT/CGGTTAAAGC	<i>Xho I</i>
CFP-10	Forward TAGA/AGCTTGATATGGGAGCAGAGATGAAGACCGATG	<i>Hind III</i>
	Reverse GAAGCCCATTGCGAGGATGAC <u>CGCCGG</u> /CGCTA	<i>Not I</i>

PCRs were performed in a 25 µl volumes containing 100 ng of template DNA, 0.5 µl (0.5) µM of each primer, set-specific for ESAT-6 or CFP-10, 2.5 mM MgCl<sub>2</sub>, 200 µl (2.5 mM) each deoxynucleoside triphosphates (dNTP), 1X PCR buffer, and 1.5 unit of *Pfu* DNA polymerase. The following condition was used for the amplification: hot start at 94 °C for 5 min, followed by 35 cycles of

denaturation at 94 °C for 1 min; annealing at 58 °C for 45 s; and extension at 72 °C for 1 min. The PCR products were analyzed by electrophoresis on a 1.5 % agarose gel in TAE buffer and visualized by SYBR Green staining on a UV gel documentation system.

The PCR products were purified from a 1.5% low-melting agarose gel with a "PCR Product Extraction Kit" (Fermentas) according to the

manufacturer's instruction. The purity of the gel-extracted PCR product was determined on a NanoDrop ND-100 spectrophotometer.

Purified PCR products were subjected to two-step digestion with *Xba* I/*Hind* III and *Not* I/*Xba* I restriction enzymes for ESAT-6 and CFP-10, respectively. The purified, digested PCR products were ligated into pcDNA3.1(+). Standard techniques for these steps such as plasmid DNA preparation, ligation, competent cell preparation, and transformation were followed as described previously (24). Competent *E. coli* TOP10 cells (Invitrogen, Carlsbad, CA) were transformed with pcDNA3.1+/ESAT-6 and pcDNA3.1+/CFP-10 using a transformation kit (Fermantas, Lithuania). Ampicillin-resistant cultures were grown in LB medium containing 50 µl/ml of ampicillin at 37 °C with shaking until OD at 600 nm = ~ 0.5. The fidelity of the transformants was verified by PCR using ESAT-6 and CFP-10-specific primers that had previously been used for amplification. The plasmids were purified and restriction enzyme-digested. After electrophoresis on a 1.5% agarose gel, the purified plasmids were sequenced (Seq Lab, microgen).

To assess expression, four mice received 100 µg of pcDNA3.1+/ESAT-6 or pcDNA3.1+/CFP-10 recombinant plasmids by intramuscular injection. One mouse received sterile PBS and one mouse was not injected (CNT-). Total RNA was isolated from the muscle 72 hours post-inoculation using a TriPure kit (Roche). The samples were analyzed by RT-PCR with specific ESAT-6 or CFP-10 primers, GAPDH primers as an internal control and a negative control.

#### ***Inoculation of mice with plasmids encoding ESAT-6 and CFP-10***

Plasmids were purified from transformed *E. coli* Top 10 cells by the alkaline lysis method, resuspended in sterile PBS pH 7.2, and stored at -20 °C. The plasmid concentrations were measured by NanoDrop at 260 nm. Mice received injections of 100 µg of DNA resuspended in 100 µl of PBS into the right quadriceps muscle using an insulin syringe. Table 2 describes the delivery program and mouse groups.

Forty-eight mice were separated into six groups of eight mice each, and all eight in each of five groups were injected with the following:

pcDNA3.1+/ESAT-6,                    pcDNA3.1+/CFP-10,  
pcDNA3.1+/CFP-10    plus    pcDNA3.1+/CFP-10,

pcDNA3.1(+), and PPD-B. One group was kept as a control without injection (CNT-). Thirty days post-injection, the mice in each group were separated into two groups, one for a second injection, and the other for proliferation assays with spleen lymphocytes. Sixty days post-injection spleens were harvested from all remaining mice for lymphocyte proliferation assays.

#### ***Spleen lymphocyte proliferation assay (MTT assay)***

Mouse spleen cells were isolated by homogenizing the organ in RPMI 1640 medium, supplemented with penicillin (100 IU/ml), streptomycin (50 µg/ml), and 10% fetal calf serum (FCS). To isolate mononuclear cells, 5-ml aliquots of the spleen cell suspension were layered onto 2.5 ml of Ficoll (Sigma) and centrifuged at 1,000 × g for 15 min at room temperature. The cells were then gently removed from the medium-Ficoll interface and washed with RPMI medium. The isolated lymphocytes were resuspended in 5 ml of RPMI complete medium and counted on a hemocytometer.

The lymphocytes (5 × 10<sup>4</sup>/well) were plated in duplicate in 96-well tissue culture plates and stimulated with 25 µg of PPD-B for 72 h in 5% CO<sub>2</sub>, 95% humidified air. In each plate, at least 4 wells were considered as negative controls, without adding PPD-B. Concanavalin A (Con A), 5 µg/ml, was added as a positive control in 4 wells to determine the proliferative response of cultured lymphocytes. Then, 10 µl of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Sigma) (5 mg/ml) were added to each well, plates were incubated at 37 °C for 4 h, and 100 µl of isopropanol with 0.04 N HCl was added and mixed thoroughly by repeated pipetting for color development. After 30 minutes the absorbance was measured using an enzyme-linked immunosorbent assay (ELISA) plate reader at a wavelength of 570 nm.


#### ***Statistical analysis***

Prism (Version 4, GraphPad Software, Inc.) was used for statistical analyses. The statistical significance of the difference between groups was determined by the one-way ANOVA test. P < 0.05 was considered significant.

## Results

### Cloning

The genes encoding ESAT-6 and CFP-10 from *M. bovis AN5* were separately cloned into the pcDNA3.1+ expression vector. The integrity of the constructed vectors pcDNA3.1+/ESAT-6 and pcDNA3.1+/CFP-10 was confirmed by PCR (Fig. 1), restriction digestion analysis, and sequencing.




**Fig. 1.** Agarose gel electrophoresis of ESAT-6 (290 bp) and CFP-10 (300 bp) PCR products, pcDNA3.1+/ESAT-6, and pcDNA3.1+/CFP-10 were used as templates for amplification. Lane M100: 100 bp DNA ladder (Fermentas).

### Proliferation assays

The means of the optical densities (OD) with standard deviations (SD) for mice groups are shown in Table 3. Optical density is an index for lymphocyte proliferation.

The results of the MMT assays after the first plasmid injections (I) are shown in Fig. 3. Lymphocytes of mice immunized with pcDNA3.1+/ESAT-6, and/or pcDNA3.1+/CFP-10, and PPD-B, were stimulated significantly more than those of the control groups that received PBS, pcDNA3.1(+), or no injection. This proliferation was significantly greater in the group that received both


To confirm that the constructs are functional in mammalian cells, they were injected into mouse muscle, and mRNA expression was evaluated by RT-PCR. The presence of the expected amplicons following RT-PCR indicated that the plasmids were transcribed in the myocytes (Fig. 2).



**Fig. 2.** Agarose gel electrophoresis of ESAT-6 and CFP-10 RT-PCR products. Lanes 1 and 2: ESAT-6 (290 bp), lanes 3 and 4: CFP-10 (300 bp), lane M100: 100-bp DNA ladder (Fermentas). In negative control was not found any amplification.

recombinant plasmids than either group that received either recombinant plasmid alone. Proliferation was greater in all treated groups than control groups. Proliferation was also greater in the group that received both plasmids than the groups that received either plasmid individually. Results were analyzed using *Bonferroni's Multiple Comparison Test*.

The statistical analyses of the MTT assays from the first and second injections showed the only group that was found significantly different between injections I and II was the ES+CF group.



**Fig. 3.** The comparison of MMT assay results in mice groups in two inoculations (first: I & second: II). The proliferation has been decreased significantly in ES+CF group after booster. Groups which received ES: pcDNA3.1+/ESAT-6, CF: pcDNA3.1+/CFP-10, ES+CF: pcDNA3.1+/ESAT-6 +pcDNA3.1+/CFP-10, pcDNA: pcDNA3.1+, PPD-B: PPD-B, are shown horizontal axis.

**Table 2.** Mice groups used in the study.

Explanations	Name	I/0	II/ 20	III/ 40
pcDNA3.1+/ESAT-6	ES	12	4 P	P -
pcDNA3.1+/CFP-10	CF	12	4 P	P -
pcDNA3.1+/ESAT-6 + pcDNA3.1+/CFP-10	ES+CF	12	4 P	P -
pcDNA3.1+	pcDNA	8	4 P	P -
PPD- Bovine	PPD-B	8	4 P	P -
Control (no injection)	CNT-	8	4 P	P -
PBS	PBS	8	4 P	P -

I: Day 0, First injection, II: Day 20, Second injection or culture of lymphocytes of spleen and proliferation assay (P), III: Day 40, Culture of lymphocytes of spleen and proliferation assay (P), \*In each cell, the number of mice per group is shown.

**Table 3.** Optical densities from MTT assays.

	OD (Mean± SD)	
	I	II
ES	0.7444±0.1294	0.7970±0.0868
ES+CF	1.2205±0.1980	1.0874±0.1689
CF	0.8496±0.1769	0.7903±0.2617
CNT-	0.4156±0.02397	0.4475±0.04175
PBS	0.4012±0.04330	0.4493±0.05730
pcDNA	0.4283±0.04898	0.4668±0.04126
PPD-B	1.2824±0.2325	1.1778±0.1345

I: Day 0, First injection,

II: Day 20, Second injection or culture of lymphocytes of spleen and proliferation assay (P).

## Discussion

Recently, awareness of the importance of bovine TB has increased, with the emphasis on detection, diagnosis, and management, but the infection has not been eliminated.

Effective resistance to mycobacterial infections is mediated by both innate and adaptive mechanisms of immunity (25). Recognition of mycobacterial antigens by T cells generates cell-mediated immunity (26, 27). Macrophages present antigens via both class I and class II major histocompatibility complex (MHC) molecules, resulting in effector CD4 and CD8 T cells that secrete cytokines, including gamma interferon (IFN- $\gamma$ ), and give rise to macrophage activation and intracellular killing of the organism (27, 28).

The identification of strong antibody responses against CFP-10 and ESAT-6 proteins resulted in their wide use for the serodiagnostic detection of TB infections (30-32). Application of these proteins as vaccine candidates is controversial. This controversy may be caused by the lack of potency of these antigens to stimulate cell-mediated immune responses.

We demonstrated lymphocyte proliferation in mice that were injected with the recombinant plasmids, indicating that ESAT-6 and CFP-10 antigens were expressed. We detected no significant difference in proliferation potency between the two greater recombinant plasmids, but proliferation was in the

mice co-immunized with both plasmids than those immunized with either plasmid alone. Lymphocyte proliferation was significantly higher after the first injection than the second in the co-immunized mice.

Proliferation assays using lymphocytes from PBS- or pcDNA3.1-injected mice were not significantly different than those of uninjected mice (Fig. 3).

In group that received PPD-B, we found a non-significant increase in lymphocyte proliferation compared with control groups. Because PPD-B includes ESAT-6 and CFP-10, it is possible that modulatory effects of other proteins present in PPD-B may suppress the proliferative effects of ESAT-6 and CFP-10 seen in our study.

Further studies to more completely characterize the effects of our construct, have been proposed. Identification of the cytokines produced is essential to see which types of T cells; TH1 and/or TH2, are evoked following immunizations using different treatments and delivery routes.

## Acknowledgements

This study is founded by Razi Vaccine & Serum Research Institute (RVSRI) and hereby we express our thanks to the supportive personnel of Razi Institute in Mashhad, AliReza Adeli, Shahrokh Sarmadi and Kazem Boozari.

## References

1. Cosivi O, Grange J, Daborn C, Raviglione M, Fujikura T, Cousins D, et al. Zoonotic tuberculosis due to *Mycobacterium bovis* in developing countries. *Emerg Infect Dis*. 1998 Jan-Mar;4(1):59-70.
2. Brunning-Fann C, Schmitt S, Fitzgerald S, Fierke J, Friedrich P, Kaneene J, et al. Bovine tuberculosis in free-ranging carnivores from Michigan. *J Wild Dis*. 2001 Jan;37(1):58-64.
3. Müller B, Dürre S, Alonso S, Hattendorf J, Laisse C, Parsons S, et al. Zoonotic *Mycobacterium bovis*-induced Tuberculosis in Humans. *Emerg Infect Dis*. 2013 Jun;19(6):899-908.
4. Kubica T, Rüsch-Gerdes S, Niemann S. *Mycobacterium bovis* subsp. *caprae* Caused One-Third of Human *M. bovis*-Associated Tuberculosis Cases Reported in Germany between 1999 and 2001. *J Clin Microbiol*. 2003 Jul;41(7):3070-7.
5. Tollesen S, Vordermeier M, Olsen I, Storset A, Reitan L, Clifford D, et al. DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants. *Scand J Immunol*. 2003 Mar;57(3):229-38.
6. Hardie R, Watson J. *Mycobacterium bovis* in England and Wales: past, present and future. *Epidemiol Infect*. 1992 Aug;109(1):23-33.
7. de Kantor I, Ambroggi M, Poggi S, Morcillo N, Da Silva Telles M, Osório Ribeiro M, et al. Human *Mycobacterium bovis* infection in ten Latin American countries. *Tuberculosis (Edinb)*. 2008 Jul;88(4):358-65.
8. Barreto ML, Pereira SM, Ferreira AA. BCG vaccine: Efficacy and indications for vaccination and revaccination. *J Pediatr (Rio J)*. 2006 Jul;82(3 Suppl):S45-54.
9. Fine PE. Variation in protection by BCG: Implications of and for heterologous immunity. *Lancet*. 1995 Nov;346(8986):1339-45.
10. Eddine A, Baumann S, Kaufmann S. New tuberculosis vaccines approaching clinical trial- An overview. *Drug Discovery Today: Therapeutic Strategies*. 2006 May;3(2):113-9.

11. Skinner M, Prestidge R, Yuan S, Strabala T, Tan P. The ability of heat-killed *Mycobacterium vaccae* to stimulate a cytotoxic T-cell response to an unrelated protein is associated with a 65 kilodalton heat-shock protein. *Immunology*. 2001 Feb;102(2):225-33.
12. Sable S, Kalra M, Verma I, Khuller G. Tuberculosis subunit vaccine design: The conflict of antigenicity and immunogenicity. *Clin Immunol*. 2007 Mar;122(3):239-51.
13. Renshaw P, Lightbody K, Veverka V, Musckett F, Kelly G, Frenkel T, et al. Structure and function of the complex formed by the tuberculosis virulence factors CFP-10 and ESAT-6. *EMBO J*. 2005 Jul;24(14):2491-8.
14. Berthet F, Rasmussen P, Rosenkrands I, Andersen P, Gicquel B. A *Mycobacterium tuberculosis* operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). *Microbiology*. 1998 Nov;144(Pt 11):3195-203.
15. Andersen P, Askgaard D, Gottschau A, Bennedsen J, Nagai S, Heron I. Identification of immunodominant antigens during infection with *Mycobacterium tuberculosis*. *Scand J Immunol*. 1992 Dec;36(6):823-31.
16. Sørensen A, Nagai S, Houen G, Andersen P, Andersen A. Purification and characterization of a low-molecular-mass T-cell antigen secreted by *Mycobacterium tuberculosis*. *Infect Immun*. 1995 May;63(5):1710-7.
17. Hoff S, Abebe M, Ravn P, Range N, Malenganisho W, Rodrigues D, et al. Evaluation of *Mycobacterium tuberculosis*-specific antibody responses in populations with different levels of exposure from Tanzania, Ethiopia, Brazil, and Denmark. *Clin Infect Dis*. 2007 Sep;45(5):575-82.
18. Kunmath-Velayudhan S, Salamon H, Wang H, Davidow A, Molina D, Huynh V, et al. Dynamic antibody responses to the *Mycobacterium tuberculosis* proteome. *Proc Natl Acad Sci U S A*. 2010 Aug;107(33):14703-8.
19. Xu Y, Wang B, Chen J, Wang Q, Zhu B, Shen H, et al. Chimaeric protein improved immunogenicity compared with fusion protein of Ag85B and ESAT-6 antigens of *Mycobacterium tuberculosis*. *Scand J Immunol*. 2006 Nov;65(5):476-81.
20. Olsen A, Williams A, Okkels L, Hatch G, Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. *Infect Immun*. 2004 Oct;72(10):6148-50.
21. Teixeira F, Teixeira H, Ferreira A, Rodrigues M, Azevedo V, Macedo G, et al. DNA vaccine using *Mycobacterium bovis* Ag85B antigen induces partial protection against experimental infection in BALB/c mice. *Clin Vaccine Immunol*. 2006 Aug;13(8):930-5.
22. Huygen K, Content J, Denis O, Montgomery D, Yawman A, Deck R, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. *Nat Med*. 1996 Aug;2(8):893-8.
23. Fan X, Gao Q, Fu R. Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of *Mycobacterium tuberculosis* in a mouse model. *Microbiol Res*. 2009;164(4):374-82.
24. Russell Sa. *Molecular Cloning: A Laboratory Manual*. 3rd ed, New York: Cold Spring Harbor Laboratory Press; 2001 Jan.
25. Flynn J, Chan J. Immunology of tuberculosis. *Annu Rev Immunol*. 2001 Apr;19:93-129.
26. Marino S, Pawar S, Fuller C, Reinhart T, Flynn J, Kirschner D. Dendritic cell trafficking and antigen presentation in the human immune response to *Mycobacterium tuberculosis*. *J Immunol*. 2004 Jul;173(1):494-506.
27. Ordway D, Henao-Tamayo M, Shanley C, Smith E, Palanisamy G, Wang B, et al. Influence of *Mycobacterium bovis* BCG vaccination on cellular immune response of guinea pigs challenged with *Mycobacterium tuberculosis*. *Clin Vaccine Immunol*. 2008 Aug;15(8):1248-58.
28. Bold T, Ernst J. CD4+ T cell-dependent IFN- $\gamma$  production by CD8+ effector T cells in *Mycobacterium tuberculosis* infection. *J Immunol*. 2012 Sep;189(5):2530-6.
29. Silveira H, Ordway D, Dockrell H, Jackson M, Ventura F. Cell-mediated immune responses to mycobacterial antigens in patients with pulmonary tuberculosis and HIV infection. *Clin Exp Immunol*. 1997 Oct;110(1):26-34.
30. Ganguly N, Siddiqui I, Sharma P. Role of *M. tuberculosis* RD-1 region encoded secretory proteins in protective response and virulence. *Tuberculosis (Edinb)*. 2008 Nov;88(6):510-7.
31. Kumar G, Dagur P, Singh P, Shankar H, Yadav V, Katoch V, et al. Serodiagnostic efficacy of *Mycobacterium tuberculosis* 30/32-kDa mycolyl transferase complex, ESAT-6, and CFP-10 in patients with active tuberculosis. *Arch Immunol Ther Exp (Warsz)*. 2010 Feb; 58(1):57-65.
32. Ireton G, Greenwald R, Liang H, Esfandiari J, Lyashchenko K, Reed S. Identification of *Mycobacterium tuberculosis* antigens of high serodiagnostic value. *Clin Vaccine Immunol*. 2010 Oct;17(10):1539-47.